$11.20
+2.0%AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
ANGO โข NASDAQ
| AngioDynamics, Inc. Income Statement | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 | May 2015 | May 2014 | May 2013 | May 2012 | May 2011 | May 2010 | May 2009 | May 2008 | May 2007 | May 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
292.5M | 303.9M | 338.8M | 316.2M | 291M | 264.2M | 359.5M | 344.3M | 349.6M | 353.7M | 357M | 354.5M | 342M | 221.8M | 216M | 216M | 195.1M | 166.5M | 112.2M | 78.5M | |
GROSS PROFIT | ||||||||||||||||||||
(134.8M) | (149.2M) | (164.5M) | (150.5M) | (134.2M) | (113.9M) | (114.6M) | (117.8M) | (125.8M) | (179.6M) | (180.7M) | (174.3M) | (173.4M) | (96.6M) | (90M) | (89.1M) | (75M) | (63.9M) | (46.1M) | (32.9M) | |
157.7M | 154.7M | 174.2M | 165.7M | 156.8M | 150.3M | 156M | 143.9M | 144M | 174.3M | 175.8M | 180.2M | 168.5M | 125.3M | 125.7M | 127M | 120.1M | 102.6M | 66.2M | 45.5M | |
OPERATING INCOME | ||||||||||||||||||||
(197.7M) | (347.1M) | (225.4M) | (194.2M) | (192.1M) | (317.4M) | (165.4M) | (158M) | (155.1M) | (173.3M) | (179.2M) | (169.7M) | (162.2M) | (129.2M) | (113.7M) | (106.1M) | (104M) | (86.4M) | (77.4M) | (35.2M) | |
(145.2M) | (144M) | (144.3M) | (133.8M) | (117.2M) | (116.5M) | (116.1M) | (108.5M) | (110.2M) | (114.1M) | (110.5M) | (109.2M) | (102.2M) | (82.8M) | (76M) | (77.4M) | (76.9M) | (61.5M) | (56.8M) | (29.3M) | |
(26.2M) | (31.5M) | (29.9M) | (30.7M) | (36.4M) | (29.7M) | (29.4M) | (25.5M) | (25.3M) | (25.1M) | (26.9M) | (27.5M) | (26.3M) | (20.5M) | (21.4M) | (19.3M) | (17.9M) | (14.4M) | (20.6M) | (5.9M) | |
-40M | -192.4M | -51.2M | -28.5M | -35.3M | -167.1M | -9.4M | -14.2M | -11.2M | 1M | -3.4M | 10.5M | 6.3M | -3.9M | 12M | 20.9M | 16.1M | 16.2M | -11.2M | 10.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (2.7M) | (688K) | (861K) | (907K) | (5.1M) | (3.1M) | (2.8M) | (3.4M) | (3.2M) | (3.7M) | (5.3M) | (508K) | (499K) | (672K) | (731K) | (0.0) | (0.0) | (0.0) | |
978K | 1.6M | -2.7M | -688K | -861K | -907K | -5.1M | -3.1M | -2.8M | -3.4M | -3.2M | -3.7M | -5.2M | 582K | 238K | 41K | 828K | 0.0 | 0.0 | 0.0 | |
(26.2M) | (171.6M) | (51.3M) | (29.7M) | (38.5M) | (171.2M) | (25.4M) | (29.6M) | (25M) | (33.9M) | (40.3M) | (29.4M) | (33.6M) | (25.2M) | (16.4M) | (9.5M) | (9.1M) | (10.5M) | (0.0) | (0.0) | |
5.9M | 797K | -3.3M | -1.5M | -769K | -1M | -5.3M | -3.1M | -3.1M | -4.3M | -4.7M | -5.3M | -7.9M | -1.5M | -1.3M | -1.3M | -952K | 1.1M | 4.1M | 816K | |
-34M | -191.6M | -54.4M | -29.9M | -36.1M | -168.1M | -14.7M | -17.3M | -14.3M | -3.3M | -8.1M | 5.2M | -1.6M | -5.4M | 10.7M | 19.6M | 15.2M | 17.3M | -7.2M | 11.1M | |
NET INCOME | ||||||||||||||||||||
-39K | -7.3M | -2M | -3.4M | -4.5M | -1.3M | -3.6M | -11M | -7.2M | (40.3M) | -4.7M | (2.8M) | -376K | -239K | (2.6M) | (7.3M) | (5.2M) | (6.4M) | (2M) | (4.3M) | |
-34M | -184.3M | -52.4M | -26.5M | -31.5M | -166.8M | 61.3M | 16.3M | -7.1M | -43.6M | -3.4M | 2.3M | -1.2M | -5.2M | 8.1M | 12.3M | 9.9M | 10.9M | -9.1M | 6.9M |
ANGO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 23, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 02, 2026 | February 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | January 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 14, 2026 | January 14, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | January 06, 2026 | November 30, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 02, 2025 | October 02, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 02, 2025 | August 31, 2025 | 2025 |
Continue your ANGO research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.